In triple-negative BCSs, treatment with ERβ antagonist PHTTP led to a decrease of mammosphere formation and tumor volume, suggesting that this receptor might be a potential target for a stem cell–specific therapy [52]. The gene discussed is ESR2; the disease is neoplasm.